Table 1 Demographics and clinical characteristics
Parameters | Total(n = 112) | Response group(n = 89) | Refractory group(n = 23) | p-value |
|---|---|---|---|---|
Age, years | 55.5 ± 10.2 | 55.2 ± 10.9 | 55.7 ± 10.8 | *0.843 |
Sex, Male: Female | 81:31:00 | 65:24:00 | 16:07 | †0.657 |
DM duration, years | 10.5 ± 7.6 | 9.3 ± 6.8 | 13.2 ± 8.1 | ‡0.063 |
severe NPDR, n(%) | 91(81.3%) | 70(78.6%) | 21(91.3%) | †0.237 |
HTN, n(%) | 83(74.1%) | 66(74.2%) | 17(73.9%) | †0.782 |
Hyperlipidemia, n(%) | 72(64.2%) | 60(67.4%) | 12(52.2%) | †0.283 |
CVA history, n(%) | 6(0.05%) | 4(0.04%) | 2(0.08%) | § 0.212 |
CVD history, n(%) | 7(0.06%) | 5(0.05%) | 2(0.08%) | § 0.276 |
insulin using, n(%) | 38(33.9%) | 27(30.3%) | 11(47.8%) | †0.102 |
PreCMT, µ | 456.3 ± 71.8 | 450.2 ± 62.3 | 465 ± 73.3 | ‡0.113 |
PreBCVA, logMAR | 0.52 ± 0.23 | 0.50 ± 0.22 | 0.54 ± 0.24 | ‡0.507 |
albuminuria, n(%) | 36(32.1%) | 23(25.8%) | 13(56.5%) | †0.082 |
BUN, mg/dL | 27.9 ± 11.1 | 26.7 ± 8.4 | 29.5 ± 13.3 | ‡0.121 |
Creatinine, mg/dL | 2.8 ± 1.0 | 2.3 ± 1.2 | 3.5 ± 0.9 | ‡0.076 |
eGFR, mL/min/1.7m2 | 22.9 ± 11.8 | 26.8 ± 12.5 | 16.6 ± 10.6 | ‡0.012 |
HbA1c, % | 7.45 ± 2.62 | 7.28 ± 2.34 | 7.88 ± 2.93 | ‡0.026 |
Total cholesterol, mg/dL | 149.3 ± 36.5 | 147.4 ± 40.5 | 151.2 ± 28.7 | *0.418 |